Prognostic significance of fluorescent In Situ hybridisation in the follow-up of non-muscle-invasive bladder cancer

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4761-4765

  Maffezzini, Massimo ^a   Campodonico, Fabio ^a   Capponi, Giacomo ^a   Canepa, Giorgio ^a   Casazza, Stefania ^a   Bandelloni, Roberto ^a   Tamagno, Stefania ^a   Puntoni, Matteo ^a  

^a GALLIERA HOSPITAL   (Italy)

Author keywords

Bladder caner; Prognosis; Recurrence; Urinary fish test; UroVysion assay

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER RECURRENCE; CHROMOSOME 17; CHROMOSOME 3; CHROMOSOME 7; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL EVALUATION; CYSTOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CYSTOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 78650239452     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Colombel M, Soloway M, Akaza H, A Böhle, J Palou, R Buckley, D Lamm, M Brausi, A Witjes and Persad R: Epidemiology, staging, grading, and risk stratifications of bladder cancer. Eur Urol (Suppl) 7: 618-626, 2008.
2. van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR: Recurrence and progression of disease in non-muscle invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56: 430-442, 2009.
3. Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW and Kurth K: Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49: 466-477, 2006.
4. Mahdy E, Yoshihiro S, Zech L, Wester K, Pan Y, Busch C, Döhner H, Kallioniemi O, Bergerheim U and Malmström PU: Comparison of comparative genomic hybridization, fluorescence in situ hybridization and flow cytometry in urinary bladder cancer. Anticancer Res 19(1A): 7-12, 1999.
5. Hailing KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB and O'Kane DJ: A comparison of BTA stat, hemoglobin dipstik telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 167: 2001-2006, 2006.
6. Hailing KC and Kipp BR: Bladder cancer detection using FISH (UroVysion assay). Adv Anat Pathol 15: 279-286, 2008.
7. Mian C, Lodde M, Comploj E, Lusuardi L, Palermo S, Mian M, Maier K and Pycha A: Multiprobe fluorescence in situ hybridization: prognostic perspectives in superficial bladder cancer. J Clin Pathol 59: 984-987, 2006.
8. Whitson J, Berry A, Carroll P and Konety B: A multicolour fluorescence in situ hybridization test predicts recurrence in patients with high-risk superficial bladder tumours undergoing intravesical therapy. BJU Int 104: 336-339, 2009.
9. Sarosdy MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, Zadra J, Burzon D, Osher G, Bridge JA, Anderson S, Johansson SL, Lieber M, Soloway M and Flom K: Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 68: 1950-1954, 2002.
10. Moonen PM, Peelen P, Kiemeney LA, Boon ME, Schalken JA and Witjes JA: Quantitative cytology on bladder wash versus voided urine: a comparison of results. Eur Urol 49: 1044-1049, 2006.
11. Papanicolaou GN and Marshall VF: Urine sediment smears as a diagnostic procedures in cancers of the urinary tract. Science 101: 519-520, 1945.
12. Bubendorf L and Grilli B: UroVysion multiprobe FISH in urinary cytology. Methods Mol Med 97: 117-131, 2004.
13. Kaplan FL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
14. Cox DR: Regression models and life tables with discussion. J Roy Stat Soc B 34: 187-192, 1972.
15. Gudjónsson S, Isfoss BL, Hansson K, Domanski AM, Warenholt J, Soller W, Lundberg LM, Liedberg F, Grabe M and Månsson W: The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 54: 402-408, 2008.
16. Pycha A, Lodde M, Comploj E, Negri G, Egarter-Vigl E, Vittadello F, Lusuardi L, Palermo S and Mian C: Intermediate-risk urothelial carcinoma: an unresolved problem? Urology 63: 472-475, 2004.
17. Jung G, Reeder GE, Cox C, Siddiqui JF, O'Connell MJ, Collins L, Yang Z, Messing EM and Wheeless LL: Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence. J Urol 162: 1900-1903, 1999.
18. Gofrit ON, Zorn KC, Silvestre J, Shalhav AL, Zagaja GP, Msezane LP and Steinberg GD: The predictive value of multi-target fluorescent in situ hybridazation in patients with a history of bladder cancer. Urol Oncol 26: 246-249, 2008.
19. Babjuk M, Oosterlink W, Sylvester R, Kaasinen E, Bohle A and Palou-Redorta RJ: European Association of Urology EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54: 303-314, 2008.